Mayne Pharma Group Limited (MAYNF)
USD 4.25
(-2.3%)
USD 4.25
(-2.3%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 31.64 Million AUD | -18.28% |
| 2023 | 47.5 Million AUD | -88.52% |
| 2022 | 413.66 Million AUD | 19.27% |
| 2021 | 346.81 Million AUD | -12.87% |
| 2020 | 398.04 Million AUD | 7.76% |
| 2019 | 369.38 Million AUD | -1.28% |
| 2018 | 374.19 Million AUD | 9.98% |
| 2017 | 340.24 Million AUD | 338.07% |
| 2016 | 77.67 Million AUD | 25.77% |
| 2015 | 61.75 Million AUD | 28.58% |
| 2014 | 48.03 Million AUD | 2.85% |
| 2013 | 46.69 Million AUD | 0.0% |
| 2012 | - AUD | -100.0% |
| 2011 | 2.33 Million AUD | -72.85% |
| 2010 | 8.61 Million AUD | 387579.03% |
| 2009 | 2222.00 AUD | -60.01% |
| 2008 | 5556.00 AUD | -37.5% |
| 2007 | 8889.00 AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 31.64 Million AUD | -13.49% |
| 2024 Q4 | 31.64 Million AUD | 22.7% |
| 2024 Q2 | 36.57 Million AUD | 10.48% |
| 2024 FY | 38.82 Million AUD | -18.28% |
| 2024 Q1 | 33.1 Million AUD | -92.0% |
| 2023 Q2 | 81.23 Million AUD | 3.9% |
| 2023 FY | 47.5 Million AUD | -88.52% |
| 2023 Q1 | 78.18 Million AUD | -81.1% |
| 2023 Q4 | 413.66 Million AUD | 842.55% |
| 2023 Q3 | 43.88 Million AUD | -45.97% |
| 2022 Q2 | 387.26 Million AUD | 0.67% |
| 2022 Q4 | 413.66 Million AUD | 0.64% |
| 2022 FY | 413.66 Million AUD | 19.27% |
| 2022 Q3 | 411.04 Million AUD | 6.14% |
| 2022 Q1 | 384.68 Million AUD | 10.92% |
| 2021 Q1 | 351.61 Million AUD | -11.66% |
| 2021 FY | 346.81 Million AUD | -12.87% |
| 2021 Q2 | 352.1 Million AUD | 0.14% |
| 2021 Q4 | 346.81 Million AUD | 0.52% |
| 2021 Q3 | 345.01 Million AUD | -2.01% |
| 2020 Q4 | 398.04 Million AUD | 0.03% |
| 2020 FY | 398.04 Million AUD | 7.76% |
| 2020 Q2 | 388.69 Million AUD | 0.74% |
| 2020 Q3 | 397.92 Million AUD | 2.38% |
| 2020 Q1 | 385.84 Million AUD | 4.46% |
| 2019 Q4 | 369.38 Million AUD | -0.11% |
| 2019 FY | 369.38 Million AUD | -1.28% |
| 2019 Q3 | 369.79 Million AUD | -6.28% |
| 2019 Q1 | 394.57 Million AUD | 5.45% |
| 2019 Q2 | 394.57 Million AUD | 0.0% |
| 2018 Q4 | 374.19 Million AUD | 0.02% |
| 2018 Q2 | 359.08 Million AUD | 0.0% |
| 2018 FY | 374.19 Million AUD | 9.98% |
| 2018 Q1 | 359.08 Million AUD | 5.54% |
| 2018 Q3 | 374.13 Million AUD | 4.19% |
| 2017 Q3 | 340.13 Million AUD | 8.64% |
| 2017 Q2 | 313.07 Million AUD | 0.0% |
| 2017 Q4 | 340.24 Million AUD | 0.03% |
| 2017 Q1 | 313.07 Million AUD | 303.08% |
| 2017 FY | 340.24 Million AUD | 338.07% |
| 2016 FY | 77.67 Million AUD | 25.77% |
| 2016 Q1 | 64.79 Million AUD | 4.92% |
| 2016 Q4 | 77.67 Million AUD | 1.75% |
| 2016 Q3 | 76.33 Million AUD | 17.8% |
| 2016 Q2 | 64.79 Million AUD | 0.0% |
| 2015 Q3 | 61.75 Million AUD | 4.89% |
| 2015 Q2 | 58.87 Million AUD | 0.0% |
| 2015 FY | 61.75 Million AUD | 28.58% |
| 2015 Q4 | 61.75 Million AUD | 0.0% |
| 2015 Q1 | 58.87 Million AUD | 22.59% |
| 2014 FY | 48.03 Million AUD | 2.85% |
| 2014 Q2 | 55.53 Million AUD | 0.0% |
| 2014 Q3 | 48.03 Million AUD | -13.51% |
| 2014 Q4 | 48.03 Million AUD | 0.0% |
| 2014 Q1 | 55.53 Million AUD | 18.92% |
| 2013 FY | 46.69 Million AUD | 0.0% |
| 2013 Q3 | 46.69 Million AUD | 0.0% |
| 2013 Q4 | 46.69 Million AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2012 FY | - AUD | -100.0% |
| 2011 FY | 2.33 Million AUD | -72.85% |
| 2011 Q4 | 2.33 Million AUD | 0.0% |
| 2010 Q4 | 8.61 Million AUD | 0.0% |
| 2010 FY | 8.61 Million AUD | 387579.03% |
| 2009 Q4 | 2222.00 AUD | 0.0% |
| 2009 FY | 2222.00 AUD | -60.01% |
| 2008 FY | 5556.00 AUD | -37.5% |
| 2008 Q4 | 5556.00 AUD | 0.0% |
| 2007 FY | 8889.00 AUD | 0.0% |
| 2007 Q4 | 8889.00 AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AstraZeneca PLC | 28.58 Billion USD | 99.889% |
| Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | 99.924% |
| CSPC Pharmaceutical Group Limited | 99.64 Million USD | 68.247% |
| Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | 25.144% |
| Novartis AG | 26.34 Billion USD | 99.88% |
| PT Kalbe Farma Tbk. | 40.4 Million USD | 21.692% |